Oculis Holding AG (ICE:OCS)
Iceland · Delayed Price · Currency is ISK | Market Cap | 196.14B +72.5% |
| Revenue (ttm) | 189.57M +74.8% |
| Net Income | -15.65B |
| EPS | -299.48 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,994 |
| Average Volume | 20,230 |
| Open | 3,230.00 |
| Previous Close | 3,280.00 |
| Day's Range | 3,230.00 - 3,290.00 |
| 52-Week Range | 1,965.00 - 3,670.00 |
| Beta | 0.21 |
| RSI | 47.56 |
| Earnings Date | May 7, 2026 |
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da... [Read more]
Financial Performance
In 2025, Oculis Holding AG's revenue was 1.20 million, an increase of 74.78% compared to the previous year's 686,000. Losses were -98.96 million, 15.4% more than in 2024.
Financial numbers in CHF Financial StatementsNews
Oculis Publishes Invitation to the Annual General Meeting
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May...
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant...
Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference
Three late-stage assets are advancing in large ophthalmic and neuro-ophthalmic markets, with OCS-01 phase III results expected in June, licaminlimab targeting a genotype-defined dry eye population, and privosegtor in registrational trials for rare optic neuropathies. Strong financials and regulatory support position the pipeline for multiple milestones through 2027.
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, April 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Oculis to Participate in Upcoming Investor Conferences
ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophtha...
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant...
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical ne...
Oculis Holding AG Transcript: Leerink Global Healthcare Conference 2026
Three phase III programs are advancing, with a topical DME therapy nearing pivotal data and a biomarker-driven dry eye trial set for Q4 results. Neuroprotection candidate Privosegtor shows strong efficacy in optic neuritis, with premium pricing anticipated.
Oculis Publishes 2025 Consolidated Financial Statements
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A,...
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
ZUG, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
Oculis Appoints Katie Kazem as Chief Legal Officer
ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significan...
Oculis Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
Three late-stage assets are advancing: OCS-01 for DME expects phase III results in Q2 and targets 2027 approval; Licaminlimab targets dry eye with a precision approach and 2026 readout; Privosegtor leads in neuroprotection with phase III trials and breakthrough status. Rapid adoption and large market opportunities are expected, backed by strong execution and financial stability.
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significan...
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing i...
Oculis Holding AG Transcript: Stifel 2025 Healthcare Conference
The company is advancing late-stage programs in neuro-ophthalmology and ophthalmology, with Privosegtor showing strong efficacy in acute optic neuritis and moving into pivotal trials for AON and NAION. OCS-01 and OCS-02 target DME and dry eye, with innovative approaches and significant market potential.
Oculis Holding AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Three late-stage assets are advancing, led by OCS-05 for acute optic neuritis, which showed strong neuroprotection and is entering two phase III trials. Licaminlimab targets dry eye disease with a precision medicine approach, and OCS-01 is in phase III for DME. Cash runway extends to 2029.
Oculis Reports Q3 2025 Financial Results and Provides Company Update
ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteriti...
Oculis to Participate in Upcoming November Investor Conferences
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significan...
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to ad...
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neur...
Oculis Holding AG Transcript: Status Update
Privosegtor advances to registration trials for AON and NAION after FDA alignment, with PIONEER-1 starting in Q4 2025 and PIONEER-3 for NAION in mid-2026. Both indications represent multi-billion dollar opportunities, and trial designs mirror the successful ACUITY phase II study.
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior I...
Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities
ZUG, Switzerland, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1...
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial Privosegtor ACUIT...